课题基金 / 基金详情

Liverpool COVID-19 Drug Interactions (www.covid19-druginteractions.org)

Liverpool COVID-19 Drug Interactions (www.covid19-druginteractions.org)
利物浦 COVID-19 药物相互作用 (www.covid19-druginteractions.org)
批准号:
MR/V020498/1
负责人:
Saye Khoo
金额:
$8.43万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2020
资助国家:
英国
项目状态:
已结题
起止时间:
2020 至 --

项目摘要

项目成果

Saye Khoo的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The Liverpool University Drug Interactions group has over twenty years' experience in developing prescribing support resources in infectious diseases, demonstrated by our world-renowned HIV and Hepatitis drug interaction websites (www.hiv-druginteractions.org and www.hep-druginteractions.org) and associated Apps. In 2019, these websites had over 50,000 unique monthly visitors searching for >4.5 million interactions. Our websites are recommended in over 30 international treatment guidelines and many national guidelines. In response to the COVID-19 pandemic and to address the pressing need for prescribing support for studies and clinical situations where experimental COVID-19 therapies are being used, we have developed a static drug interactions website (www.covid19-druginteractions.org) providing information on the likelihood of interactions between the experimental agents and commonly prescribed co-medications. We now have to move to develop a fully interactive and searchable website resource with an associated App. The website will be constantly updated and populated with the latest information on experimental therapies with guidance given to clinicians for managing complex patients.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
Dolutegravir pharmacokinetics during co-administration with either artemether/lumefantrine or artesunate/amodiaquine.
多替拉韦与蒿甲醚/本芴醇或青蒿琥酯/阿莫地喹联合给药期间的药代动力学。
DOI: 10.1093/jac/dkab022
发表时间: 2021
期刊: The Journal of antimicrobial chemotherapy
影响因子: --
作者: [Kawuma AN]
通讯作者: Kawuma AN
DOI: 10.1016/s2666-7568(21)00206-3
发表时间: 2021-10
期刊: The lancet. Healthy longevity
影响因子: --
作者: [Justice AC, Gordon KS, Romero J, Edelman EJ, Garcia BJ, Jones P, Khoo S, Lo Re V 3rd, Rentsch CT, Tate JP, Tseng A, Womack J, Jacobson D]
通讯作者: Jacobson D
DOI: 10.1007/s40262-021-01005-1
发表时间: 2021-07
期刊: Clinical pharmacokinetics
影响因子: 4.5
作者: [Hodge D, Back DJ, Gibbons S, Khoo SH, Marzolini C]
通讯作者: Marzolini C
Response to "A Case Report of Safe Coadministration of Amioradone With Short-Term Treatment Nirmatrelvir-Ritonavir".
对“胺碘酮与短期治疗尼尔马韦-利托那韦安全联合用药的病例报告”的回应。
DOI: 10.1002/cpt.2809
发表时间: 2023
期刊: Clinical pharmacology and therapeutics
影响因子: 6.7
作者: [Marzolini C]
通讯作者: Marzolini C
Healthy Jozi: A Staged Approach to Better Workplace Food Choices and Chronic Disease Screening and Linkage to Care
  • 批准号:
    MR/Z000467/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $248.64万
  • 财政年份:
    2024
  • 负责人:
    Saye Khoo
  • 依托单位:
AGILE: Seamless Phase I/IIa Platform for the Rapid Evaluation of Candidates for COVID-19 treatment
  • 批准号:
    MR/V028391/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $809.65万
  • 财政年份:
    2021
  • 负责人:
    Saye Khoo
  • 依托单位:
Neuropsychiatric problems related to HIV infection and antiretroviral therapy in Cape Town
  • 批准号:
    MC_PC_MR/S008829/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $8.29万
  • 财政年份:
    2019
  • 负责人:
    Saye Khoo
  • 依托单位:
Modulation of TB-HIV drug interaction by host genetic influences
  • 批准号:
    G0901364/1
  • 项目类别:
    Research Grant
  • 资助金额:
    $19.53万
  • 财政年份:
    2010
  • 负责人:
    Saye Khoo
  • 依托单位:
国内基金
海外基金
CEACAM5调控Galectin-9介导的CD4+T细胞极化在COVID-19肠屏障损伤的作用机制研究
  • 批准号:
    82370569
  • 项目类别:
    面上项目
  • 资助金额:
    49万元
  • 批准年份:
    2023
  • 负责人:
    李啸峰
  • 依托单位:
COVID-19疫情对我国儿童生长发育影响的异质性研究
  • 批准号:
    42371429
  • 项目类别:
    面上项目
  • 资助金额:
    52.00万元
  • 批准年份:
    2023
  • 负责人:
    张知新
  • 依托单位:
传染病模型的稳态切换过程研究及其在治疗COVID-19中的应用
  • 批准号:
    LQ23A010016
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2023
  • 负责人:
    罗敏
  • 依托单位:
“湿漫膜原”视角下研究加味达原饮重塑COVID-19“免疫炎症稳态”的分子机制:TLR4介导IRF3/NF-κB通路串扰
  • 批准号:
    82374291
  • 项目类别:
    面上项目
  • 资助金额:
    48万元
  • 批准年份:
    2023
  • 负责人:
    张传涛
  • 依托单位: